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ABSTRACT
Objective We conducted serosurveillance of anti- SARS- 
CoV- 2 antibodies among pregnant women attending their 
first antenatal care.
Setting The surveillance was set in one referral hospital 
in Harar, one district hospital and one health centre located 
in Haramaya district in rural eastern Ethiopia.
Participants We collected questionnaire data and a blood 
sample from 3312 pregnant women between 1 April 2020 
and 31 March 2021. We selected 1447 blood samples at 
random and assayed these for anti- SARS- CoV- 2 antibodies 
at Hararghe Health Research laboratory using WANTAI 
SARS- CoV- 2 Rapid Test for total immunoglobulin.
Outcome We assayed for anti- SARS- CoV- 2 antibodies 
and temporal trends in seroprevalence were analysed with 
a χ2 test for trend and multivariable binomial regression.
Results Among 1447 sera tested, 83 were positive for 
anti- SARS- CoV- 2 antibodies giving a crude seroprevalence 
of 5.7% (95% CI 4.6% to 7.0%). Of 160 samples 
tested in April–May 2020, none was seropositive; the 
first seropositive sample was identified in June and 
seroprevalence rose steadily thereafter (χ2 test for 
trend, p=0.003) reaching a peak of 11.8% in February 
2021. In the multivariable model, seroprevalence was 
approximately 3% higher in first- trimester mothers 
compared with later presentations, and rose by 0.75% 
(95% CI 0.31% to 1.20%) per month of calendar time.
Conclusions This clinical convenience sample illustrates 
the dynamic of the SARS- CoV- 2 epidemic in pregnant 
women in eastern Ethiopia; infection was rare before June 
2020 but it spread in a linear fashion thereafter, rather 
than following intermittent waves, and reached 10% by 
the beginning of 2021. After 1 year of surveillance, most 
pregnant mothers remained susceptible.
INTRODUCTION
In Ethiopia, the first case of COVID- 19 was 
reported on 13 March 2020. By the end of 
March 2021, there were 206 589 reports of 
COVID- 19 infection and 2865 COVID- 19- 
related deaths. In a country with an esti-
mated population, in 2019, of 112 million this 
represents a cumulative incidence of SARS- 
CoV- 2 infection of only 0.2% after a full year 
of transmission. Many cases of COVID- 19 
present with mild symptoms and, in Ethi-
opia, three quarters of PCR- positive cases 
have no symptoms.1 2 Access to PCR testing 
in Ethiopia is also sparse. Monitoring the 
epidemic by detecting symptomatic cases is, 
therefore, highly insensitive. In these circum-
stances, seroprevalence of anti- SARS- CoV- 2 
antibodies can provide a more accurate 
estimator of cumulative incidence. Under-
taking community sero- sampling during 
the pandemic is difficult when travel and 
household access are constrained by control 
measures. Expectant mothers, however, are 
likely to continue to seek health services 
throughout the pandemic and they can be 
used as a continuously available proxy popu-
lation to estimate the cumulative incidence 
among young adults.3–5 In addition, serolog-
ical surveillance is simple to implement at 
antenatal clinic (ANC) visits because anti- 
SARS- CoV- 2 antibodies can be assayed in the 
residual blood volumes of routine samples 
collected for clinical screening for anaemia 
and maternal infectious diseases.
Strengths and limitations of this study
 ► The surveillance was initiated quickly at the start 
of the pandemic and was pursued with consistent 
methods over a full calendar year.
 ► Pregnant women are consistently available for sur-
veillance throughout movement restrictions provid-
ing a practical and valid survey of seroprevalence 
trends.
 ► Results from pregnant women may not be fully rep-
resentative of older or younger women, nor of men 
at any age.
 ► SARS- CoV- 2 antibodies were assayed using a lateral 
flow device which, though convenient, has inferior 
performance characteristics to ELISA.
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Planning and provision of healthcare during a major 
epidemic like COVID- 19 pose substantial logistical 
and clinical challenges. Information on the shape of 
the epidemic curve is critical to inform public health 
responses. The dynamics of seroprevalence reflect the 
epidemic curve and can provide an estimate of the 
effective reproduction number. Seroprevalence also 
indicates the likelihood of approaching transmission 
control through population immunity. This study aimed 
to assess the trend in seroprevalence of anti- SARS- CoV- 2 
antibodies throughout the first year of the epidemic by 
assaying anti- SARS- CoV- 2 antibodies among pregnant 
women attending ANC at three different health facilities 
in the area around Harar, eastern Ethiopia.
MATERIAL AND METHODS
Study area and period
The surveillance was conducted between 1 April 2020 and 
31 March 2021 at Awoday Health Centre and Haramaya 
District Hospital, both in Haramaya district(rural), and 
in Hiwot Fana Specialized Referral University Hospital 
in Harar(urban). Hiwot Fana is the largest referral and 
teaching hospital in eastern Ethiopia and receives tertiary 
referrals from Harari region, East Oromia, Somali region 
and Dire Dawa city. It is one of the 10 regional centres 
designated by the Federal Ministry of Health to manage 
the COVID- 19 epidemic. Haramaya Hospital was rapidly 
designated a COVID- 19 treatment facility and women 
seeking ANC services were therefore referred to Awoday 
Health Centre after 16 April 2020. Ethiopia began to 
roll out COVID- 19 vaccine in the first quarter of 2021; 
however, no doses were given in the study area during the 
period this analysis covers.
Study design, population and sample size
At the end of March 2020, we integrated health facility- 
based surveillance into the routine clinical care of preg-
nant women at Hiwot Fana Hospital, Awoday Health 
Centre and Haramaya Hospital. The study population 
comprised 3390 pregnant women attending their first 
antenatal care in these three facilities during the surveil-
lance period. Because we had fewer test kits available than 
there were samples available from the clinic, we selected a 
random sample for analysis stratified on month. Initially, 
we decided to select 144 samples per month; as the sero-
prevalence was very low in the first 3 months we reset 
the sample size to 80 per month from July onwards and 
increased it to 160 per month in December once the 
seroprevalence reached 5%. In October, the number of 
samples collected was lower than the desired sample size 
and we therefore tested all of the samples (see online 
supplemental table).
A total of 78 women were excluded because they were 
not willing to provide a blood sample. Routine antenatal 
care includes serological screening for HIV, syphilis and 
toxoplasma infection during pregnancy undertaken in 
two blood samples; the first blood sample is taken at 16 
weeks’ gestation or at the first ANC visit, if later.
Sociodemographic data and information on preg-
nancy, clinical symptoms of COVID- 19 and comorbidities 
were collected by trained nurses. COVID- 19 symptoms 
were defined as at least one of cough, fever, headache or 
difficulty breathing. Data quality and completeness were 
checked daily.
Laboratory analyses
For the anti- SARS- CoV- 2 antibodies test, residual blood 
samples from the routine ANC tests were transferred to 
a test- tube containing clot activator by trained medical 
laboratory technologists working in each health facility. 
The blood samples were allowed to clot and serum was 
separated by centrifugation at 3000 RPM for 10 min. 
Serum samples were stored at 2°C–8°C at each site and 
transported in cool boxes to Hararghe Health Research 
Laboratory where they were stored at −80°C.
Samples were tested using WANTAI SARS- CoV- 2 Ab 
Rapid Test. The test is a lateral flow assay in a cassette 
format designed for the qualitative detection of total anti-
bodies to SARS- CoV- 2 in human serum. The receptor- 
binding domain of the SARS- CoV- 2 spike protein is 
bound at the Test Zone (T) and antibodies are bound 
at the Control Zone (C) of the cassette. The test has a 
sensitivity of 100% and specificity of 98.8% under vali-
dation performed by the manufacturer6; independent 
validation of the test found a sensitivity of 89%.7 All the 
stored serum samples, tests reagents and cassettes were 
brought to room temperature (15°C–30°C) 30 min before 
performing the test and checked for defects. Then, a 
10 µL of serum specimen and two drops of diluent buffer 
were added into the specimen window. Results were 
read and interpreted as reactive/positive (red line on 
C and T) or non- reactive/negative (red line on C) after 
15–20 min according to manufacturer’s instruction.6 7 
Serum samples were taken ≥14 days after a positive PCR 
test from COVID- 19 infected individuals were used as 
positive control. Samples were tested in batches of 50–60 
by a single operator. Assays without a valid reaction on the 
control line were rejected and the assay was repeated on 
a new kit.
Patient and public involvement statement
Because the surveillance was set up urgently at the begin-
ning of the pandemic we were not able to involve partici-
pants or the public in the design or set- up and because it 
was designed as an anonymous surveillance we were not 
able to provide individual feedback of the results to the 
participants. We have provided feedback of these high- 
level results through our existing community engagement 
exercises, including local radio programmes, meetings 
with local leaders and communication through health 
workers for onward dissemination.
Statistical analysis
We used STATA V.16.0 for statistical management and 
analysis. We selected a random sample of participants 
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each month using the runiform function. We estimated 
unadjusted seroprevalence of SARS- CoV- 2 IgG antibody 
with a 95% CI. We did not make adjustment for the test 
performance characteristics because the manufacturer’s 
validation assay found very high sensitivity and specificity. 
We examined the univariate association between indi-
vidual characteristics and seropositivity using χ2 test and 
multivariable associations using binomial regression. The 
trend in seropositivity with time was tested with a χ2 test 
for trend and in the multivariable model. Data used in 
the analysis are available online ( dataverse. harvard. edu).8
Ethical consideration
The surveillance was confined to residual clinical blood 
sample testing and anonymised data were collected using 
checklists to extract data from ANC cards. Bar codes, 
representing an anonymous unique identity number, 
were used to link extracted clinical and demographic 
data with test sample results. The exercise was conducted 
as part of a public health surveillance, with the approval 
of the directors of each of the three health facilities, and 
the results were made available to health facilities, the 
Regional Health Bureaux(Harari and Oromia) and the 
Ethiopian Public Health Institute. All ANC attendees 
were informed that the clinic was participating in an 
anonymous surveillance and mothers were made aware 
that the residual volumes of their blood samples would 
be made available to the surveillance laboratory. Written 
individual informed consent was not obtained.
RESULTS
Demographic characteristics of the study participants
Between 1 April 2020 and 31 March 2021 there were 
3390 first visits to the ANCs; 1568 (46.24%) at Hiwot Fana 
Hospital, 1823 (53.75%) at Awoday Health Centre and 
Haramaya Hospital. At these, we interviewed and collected 
blood samples from 3312 women. We tested a random 
sample of 1447 blood specimens (table 1); 752 (52%) 
were from Haramaya district (Awoday Health Centre and 
Haramaya Hospital) and 695 (48%) were from Hiwot 
Fana Hospital; 984 (68%) were urban residents.
Among the population sample tested, the mean (SD) 
age was 23.9 (4.7) years and ages ranged from 15 to 45 
years. The mean (SD) number of children per mother 
was 1.5 (1.8). The median (IQR) gestational age at the 
first antenatal visit was 20 (13–28) weeks. Only 51 (3.5%) 
Table 1 Characteristics of 1447 pregnant mothers attending their first antenatal care at the study clinics between April 2020 
and March 2021 and sampled at random for the study
Characteristics
Haramaya District Hiwot Fana Hospital Total
n % n % n %
Age in years
  14–19 98 13.0 74 13.5 192 13.3
  20–24 341 45.4 268 35.6 588 40.7
  25–29 181 24.1 219 31.6 400 27.7
  30–34 110 14.6 100 14.4 210 14.5
  ≥35 22 2.9 35 4.9 56 3.9
Residence
  Urban 577 76.8 407 58.7 984 68.1
  Rural 174 23.2 287 41.4 461 31.9
Number of children
  None 298 40.0 254 36.8 552 38.4
  1–5 422 56.6 401 58.1 823 57.3
  6–10 26 3.5 35 5.1 61 4.3
Trimester of visit
  First 223 29.7 143 20.6 366 25.3
  Second 416 55.3 242 34.8 658 45.5
  Third 113 15.0 310 44.6 423 29.2
Comorbidities
  None 750 99.7 689 99.1 1439 99.5
  At least one* 2 0.3 6 0.9 8 0.6
COVID- 19 symptoms†
  No 721 96.4 668 96.5 1389 96.5
  Yes 27 3.6 24 3.5 51 3.5
*Chronic liver, renal, cardiovascular or ‘other’ disease.
†At least one of cough, fever, headache or difficulty breathing.
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had COVID- 19 symptoms at the time of sampling and 
8 (<1%) had a history of comorbidity, given as chronic 
liver, renal, cardiovascular or ‘other’ disease. Respiratory 
diseases, chronic neurological disease, diabetes mellitus 
and cancer were not reported by any participant.
Seroprevalence of SARS-CoV-2 antibodies
Of 1447 samples tested, 83 (5.7%, 95% CI 4.6 to 7.0%) 
were positive for anti- SARS- CoV- 2 antibodies. The first 
seropositive sample was identified on 11 June 2020, and 
seroprevalence rose progressively thereafter, with the 
exception of March 2021, where it dropped sharply (χ2 
for trend for the whole year, p=0.003; figure 1).
Seroprevalence also varied significantly by trimester of 
pregnancy and comorbidity but not by clinic, residence or 
COVID- 19 symptoms (table 2). Given the linear growth in 
seroprevalence (figure 1) and better model fit based on 
Bayesian information criterion, we modelled prevalence 
associations as risk differences rather than risk ratios. 
Figure 1 Temporal trend of seroprevalence of anti- SARS- 
CoV- 2 antibodies among pregnant women presenting for 
first antenatal care in three antenatal clinic facilities, eastern 
Ethiopia, between 1 April 2020 and 31 March 2021.
Table 2 Seroprevalence of anti- SARS- CoV- 2 antibodies by participant characteristics
Characteristics
Tested Seropositive Seroprevalence χ2 test
N n % P value
Age in years
  14–19 192 7 3.7 0.19
  20–24 588 42 7.1
  25–29 400 24 6.0
  30–34 210 9 4.3
  ≥35 56 1 1.8
ANC
  Hiwot Fana Hospital 695 35 5.0 0.260
  Haramaya Hospital 19 0 0.0
  Awoday Health Centre 733 48 6.6
Residence
  Urban 984 57 5.8 0.910
  Rural 461 26 5.6
Number of children
  None 520 32 5.8 0.370
  1–5 778 45 5.5
  6–10 55 6 9.8
Trimester of visit
  First 366 31 8.5 0.034
  Second 658 32 4.9
  Third 423 20 4.8
Comorbidities
  None 1439 81 5.6 0.019
  At least one* 8 2 25.0
COVID symptoms†
  No 1389 82 5.9 0.240
  Yes 51 1 2.0
*Chronic liver, renal, cardiovascular or ‘other’ disease.
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In a multivariable binomial regression model, the prev-
alence difference was −3.2% (95% CI −6.7% to −0.4%) 
and −3.0% (95% CI −6.8% to −0.8%) among women in 
their second and third trimesters, respectively, compared 
with those in the first trimester and the prevalence differ-
ence was 0.75% (95% CI 0.31% to 1.20%) per month of 
calendar time.
DISCUSSION
The study provides a simple description of the dynamic of 
SARS- CoV- 2 epidemic in an area where reliable data are 
extremely rare. In a population of attendees at ANCs in 
three sites in eastern Ethiopia, antibodies against SARS- 
CoV- 2 first appeared in June 2020 and seroprevalence 
rose steadily month on month reaching approximately 
10% at the beginning of 2021. Although the point esti-
mate for March 2021 is substantially lower, the data as a 
whole evince a strong linear trend and this single estimate 
is most likely to have deviated from the general direction 
by chance. If these results are reliable, they indicate that 
the epidemic is progressing here at a considerably lower 
rate than in other settings in East Africa and that the 
greater majority of the population remains uninfected, 
suggesting that the epidemic is still at an early stage.
The principal limitations of the study are the potential 
generalisability of the population under surveillance and 
the validity of the serological assay employed. Pregnant 
women have been used as an indicator population in prior 
pandemics, including HIV,9 but also for SARS- CoV- 2, both 
in high- income settings4 5 10–14 and low- income and middle- 
income settings, including in neighbouring Kenya.3 The 
principal advantage of sampling pregnant women is that 
they remain one of the few patient groups for whom health 
services cannot be postponed until after the pandemic 
has passed. They are permitted and encouraged to attend 
even in the face of social and movement restrictions, and so 
provide a consistent and reliable sampling group. The prin-
cipal limitation of this group is their restriction on age and 
sex, however, in most settings, including other East African 
countries, seroprevalence does not vary significantly by sex 
and the cumulative incidence in women is likely to repre-
sent the infection history of both sexes.15–20 Similarly, in most 
settings young adults are the group most likely to be infected 
by SARS- CoV- 2 and so the seroprevalence estimates here are 
likely to represent the highest risk in the whole population; 
other age groups, particularly children and the elderly, are 
likely to have lower seroprevalence.17 21
The WHO has deprecated the use of rapid tests for SARS- 
CoV- 2 antibodies for individual diagnosis but recognises 
their potential value in research.22 WHO has also recom-
mended and endorsed quantitative analysis of IgG anti-
bodies using ELISA and has distributed the WANTAI ELISA 
kit to countries undertaking serosurveillance. Reliance on 
ELISA, however, limits the range of settings in which sero-
surveillance can be undertaken and lateral flow tests have 
been successfully employed for recurrent community- based 
nationwide surveys in the UK.23 When seroprevalence is low, 
as at the beginning of our study, an assay with imperfect 
specificity may detect more false positives than true positives. 
The specificity of the WANTAI rapid test has been estimated 
by the manufacturer at 98.8%. We assayed 80 samples each 
month in April and May 2020 without observing a single 
positive test, suggesting that the specificity is indeed very 
high. Even if the positive results identified in June included 
false positives, the progressive rise in seropositivity with time 
is most unlikely to be influenced materially by a small frac-
tion of false positive results.
The assay sensitivity may also be imperfect in detecting 
prior infection because the assay was originally calibrated 
against sera from symptomatic cases, who generally have 
higher antibody levels than asymptomatic individuals,24 and 
because pregnant women who were infected several months 
ago may have experienced waning of antibody levels and 
seroreversion.25–29 In general, seroreversion is less prob-
lematic in assays that measure total immunoglobulin and 
in those that target spike antigens, compared with nucleo-
capsid antigens,27 30 so the problem of waning in this study 
is unlikely to be substantial. Furthermore, if sensitivity is 
unlikely to decline over time, imperfect sensitivity would not 
affect the shape of the rising seroprevalence line, though it 
would underestimate the gradient. If, as estimated in one 
validation study, the WANTAI rapid test has a sensitivity of 
only 89%,7 adjustment for test- performance characteristics 
would elevate our reported seroprevalence results by a factor 
of 1.12.
The results are in contrast to most other settings studied 
which record a sharp take- off in seroprevalence once trans-
mission begins, often rising quickly to high levels. In Kenya 
for example, women attending an ANC in Kilifi had sero-
prevalence of 0%, 2% and 11% in consecutive months 
September–November 2021; those attending ANC in 
Nairobi had a seroprevalence of 50% in August 2020.3 The 
pattern illustrated in eastern Ethiopia is more indicative of a 
gradually spreading epidemic curve suggesting an effective 
reproduction number much closer to 1.
In Juba, South Sudan, seroprevalence was 22% in a 
household survey in August–September 202020; in Kenya, a 
national estimate for seroprevalence, based on testing blood 
transfusion donors, was 4.3% in May 2020 18% and 9.1% 
2 months later.15 Healthcare workers in Nairobi, Kenya, had 
a seroprevalence of 44% in August 2020; those in two rural 
hospitals had seroprevalence of 12%–13% in November 
2020.15 Finally, in Addis Ababa seroprevalence, estimated 
in May 2020, was 3.0%.31 Although all these studies used 
different laboratory assays and varied statistical adjustments, 
collectively, they suggest that transmission in eastern Ethi-
opia began later than in much of the rest of the region, 
including the state capital, and has progressed more slowly.
CONCLUSION
In summary, if seroprevalence is a reliable indicator of cumu-
lative incidence, SARS- CoV- 2 infection is spreading slowly 
but steadily in eastern Ethiopia. This contrasts sharply with 
the recurrent waves of PCR- positive infections apparent in 
 on D
ecem









pen: first published as 10.1136/bm






6 Assefa N, et al. BMJ Open 2021;11:e055834. doi:10.1136/bmjopen-2021-055834
Open access 
the national surveillance system. One year after the start 
of the epidemic, approximately 10% of women attending 
ANCs are seropositive implying that the COVID- 19 epidemic 
is still at an early stage in eastern Ethiopia.
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